SCHEMBL1646348

SCHEMBL1646348

Nc1ccc(N2CCN(CCc3ccco3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
GFER P55789 4/20 0.50
GAA P10253 4/20 0.50
KDM4E B2RXH2 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
RAD52 P43351 1/20 0.50
ALDH1A1 P00352 6/20 0.49
CYP2C19 P33261 2/20 0.49
LMNA P02545 2/20 0.49
CYP2C9 P11712 1/20 0.49
ALOX12 P18054 1/20 0.49
ADRA2C P18825 1/20 0.46
KMT2A Q03164 1/20 0.46
PTK2B Q14289 1/20 0.46
ESR2 Q92731 1/20 0.46
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6695193 0.88 ALDH1A1 (0.53) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL1644607 0.80 HTR1A (0.54) MAPTKMT2AHTR1APOLB
SCHEMBL1644575 0.80 HTR1A (0.44) KDM4ESMN1; SMN2ALDH1A1LMNAHTR1A
SCHEMBL8008916 0.77 KMT2A (0.53) MAPTGAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL10359673 0.77 HTR1A (0.64) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL27563249 0.76 HTR1A (0.78) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL27634364 0.75 MAPT (0.62) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL7171966 0.74 GFER (0.59) MAPTGFERKDM4ESMN1; SMN2ALDH1A1
SCHEMBL1989885 0.74 MAPT (0.46) MAPTGFERGAAKDM4ESMN1; SMN2
SCHEMBL5655420 0.73 ALDH1A1 (0.56) MAPTKDM4ESMN1; SMN2ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885GFER 3245/4885GAA 1536/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885GFER 1317/4885GAA 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.